IQ-AI Ltd on Friday said the clinical team has started a phase 2 protocol for its oncology-focused drug oral gallium maltolate, which could be a therapeutic agent for cancer.
The London-based medical services company said it will be a multicentre trial to span for about three years, with a target enrolment of about 50 to 60 patients. Firm costs are projected between $2 million and $2.5 million over the duration of the trial, which is anticipated to start in 2025.
‘IQAI anticipates making a significant contribution to the costs of the phase 2 trial, in combination with possible grants and further support from charitable foundations if necessary,’ the company said.
IQ-Ai added: ‘While we intend to focus on the current development path of GaM, we are keeping informed of those early pre-clinical projects and potential new clinical trials. Pediatric cancers for which we have rare pediatric disease designations are of particular interest.’
IQ-AI shares were flat at 1.30 pence each on Friday afternoon in London.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
